Stockreport

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data [Seeking Alpha]

Prelude Therapeutics Incorporated  (PRLD) 
PDF The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical da [Read more]